Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2022-02-15 00:00:00 ET · period of report 2022-02-14 · accession 0001062993-22-004516 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-02-15 | 2022-02-14 | ENTA | Adda Nathalie | SVP, Chief Medical Off | F - Tax | $62.49 | -954 | 35.0K | -3% | -$59.6K | |
| M | 2022-02-15 | 2022-02-14 | ENTA | Adda Nathalie | SVP, Chief Medical Off | A - Grant | $0.00 | +3,034 | 35.9K | +9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-14 | F | D | 954 | $62.49 | 34,982 | D | — | — | (F3) Represents the number of shares of common stock automatically forfeited by the reporting person to cover withholding taxes due as a result of settlement of the PSU and rTSRU awards. |
| 2 | Common | Common Stock | 2022-02-14 | A | A | 615 | $0.00 | 33,517 | D | — | — | (F1) Represents shares of Enanta common stock issued under a performance share unit ("PSU") award granted on December 20, 2019 that vested as a result of the achievement of a research and development milestone in calendar 2021 as determined by the Compensation Committee of Enanta's Board of Directors, and then settled with the issuance of the shares of Enanta common stock on February 14, 2022. |
| 3 | Common | Common Stock | 2022-02-14 | A | A | 2,419 | $0.00 | 35,936 | D | — | — | (F2) Represents shares of Enanta common stock issued under a relative total stockholder return unit ("rTSRU") award granted to the reporting person on December 20, 2019 that was subject to performance-vesting restrictions based on the relative total stockholder return of Enanta's common stock in relation to the total stockholder return of the component companies in the Nasdaq Biotech Index over a two-year period. The performance level was determined by the Compensation Committee of Enanta's Board of Directors and the rTSRU settled with the issuance of the shares of Enanta common stock on February 14, 2022. |